Relmada Therapeutics
RLMD
83 hedge funds and large institutions have $56.7M invested in Relmada Therapeutics in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 16 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
26% more capital invested
Capital invested by funds: $45M → $56.7M (+$11.8M)
4.25% less ownership
Funds ownership: 49.8% → 45.55% (-4.3%)
5% less funds holding
Funds holding: 87 → 83 (-4)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
79% less call options, than puts
Call options by funds: $296K | Put options by funds: $1.41M
Top Buyers
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.51M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$740K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$651K |
| 4 |
Two Sigma Advisers
New York
|
+$485K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$455K |
Top Sellers
RLMD Hedge Fund Activity: Q4 2023 in Review
83 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2023, worth a combined $56.7M — up 26% from $45M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of RLMD and 14 opened new positions — a net loss of 2 holders — while 19 trimmed existing stakes and 27 added.
The largest buyer was Opaleye Management, adding an estimated $2.51M. The largest seller was RTW Investments, exiting entirely with an estimated $6.4M sold.
- 83 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2023, down from 87 in Q3 2023.
- Funds reported $56.7M of Relmada Therapeutics stock for Q4 2023, up 26% quarter-over-quarter.
- 14 funds opened new Relmada Therapeutics positions in Q4 2023 and 16 closed out, a net change of -2 holders.
- The largest Relmada Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.51M added.
- The largest Relmada Therapeutics seller in Q4 2023 was RTW Investments, an estimated $6.4M sold.
Based on aggregated 13F filings for Q4 2023.